You are here: Industry Insights > gilead

News List

Gilead submits drug application to FDA for HIV treatment europeanpharmaceuticalreview
June 19, 2017
Gilead has submitted a new drug application to the US FDA for treatments of HIV.
Sanofi, Gilead eyeing the takeover of Tesaro biospectrumasia
June 14, 2017
The company that acquires Tesaro will get access to Zejula, a PARP inhibitor approved to treat women with ovarian cancer
Gilead’s Phase II study showed 99% HCV cure rates europeanpharmaceuticalreview
April 27, 2017
Gilead Sciences’ Phase II studies demonstrated HCV cure rates of 99% in children aged 6 to 11 years, and 100% in adult patients co-infected with HCV and hepatitis B virus (HBV).
What Happens if Gilead (GILD) Went Bigger Than Incyte (INCY) and Made a Play for This Pharma Giant BioSpace.com
April 11, 2017
Investors want Gilead Sciences (GILD) to buy something. And given the amount of coverage given to speculation over who Gilead might, can or should buy, it seems almost to be a hobby for a great number of people.
With Shrinking of USD 5 Billion, How Can Gilead Fill the Gap Caused by the Decline of the “Miracle D en-cphi
March 03, 2017
With Shrinking of USD 5 Billion, What Can Gilead Use to Fill the Gap Caused by the Decline of the “Miracle Drug”?
Sarepta sells FDA priority review voucher to Gilead for $125 million firstwordpharma
February 22, 2017
Sarepta Therapeutics disclosed Tuesday that it entered an agreement to sell its rare paediatric disease priority review voucher to Gilead Sciences for $125 million.
Amygdala acquires Gilead’s candidate for addiction treatment pharmafile.com
February 21, 2017
Amygdala Neurosciences has agreed an acquisition with Gilead’s GS-6637.
Gilead reports positive mid-stage data for HIV therapy bictegravir firstwordpharma
February 15, 2017
Gilead Sciences announced results from a Phase II study demonstrating that the experimental integrase strand transfer inhibitor bictegravir achieved high virologic response rates similar to ViiV Healthcare's integrase inhibitor Tivicay (dolutegravir) in t
Gilead Names GM for Canada Ops contractpharma
February 09, 2017
Brysting brings 20 years of industry experience
Gilead announces lower than expected 2017 sales guidance firstwordpharma
February 08, 2017
Gilead Sciences on Tuesday said that it anticipates full-year revenue for 2017 to be in the range of $22.5 billion to $24.5 billion, falling short of analysts' expectations of $27.9 billion.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 21 22 Next page